Stockreport

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Corporation  (RLYB) 
PDF – Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-sta [Read more]